mild cognitive impairment

Overview

Mild cognitive impairment (MCI) is a clinical syndrome characterized by measurable cognitive decline that is greater than expected for age but does not yet meet criteria for dementia. It is commonly described as an intermediate state between normal cognitive aging and dementia, and it is often used in research and clinical practice as a prodromal or risk state for neurodegenerative disease, especially Alzheimer disease. Individuals with MCI may have isolated memory impairment or deficits in other cognitive domains, while daily functional independence is largely preserved.

Biologically and medically, MCI is important because it is a major target for early detection, risk stratification, and intervention. Recent research has linked MCI to Alzheimer disease-related pathology, vascular brain injury, obstructive sleep apnoea, hearing loss, type 2 diabetes, and broader brain-aging exposures. It is also a frequent endpoint in studies of biomarkers, imaging, digital health tools, and preventive therapies aimed at slowing progression to dementia or improving cognitive and functional outcomes.

Focus of Latest Publications

Recent publications on mild cognitive impairment (MCI) have focused on both disease-modifying treatment strategies and tools for earlier detection, prognosis, and mechanistic characterization. Several studies examined MCI in the context of Alzheimer’s disease care, including a target trial emulation comparing initiation of lecanemab versus acetylcholinesterase inhibitors in patients with MCI or Alzheimer’s disease, and a deep learning prognostic framework that used a single baseline cerebrospinal fluid biomarker assessment to estimate individualized cognitive decline and time to conversion from MCI to dementia. These studies reflect growing interest in identifying which patients with MCI may benefit from earlier intervention and in improving prediction of progression.

A second theme has been biomarker discovery and biological profiling. One population-based longitudinal study used plasma proteomics and metabolomics to identify molecular signatures associated with prevalent and new-onset MCI and dementia over 3–5 years of follow-up. The investigators reported that 463 of 1,892 measured molecules were significantly associated with baseline MCI and dementia, and their best predictive model for incident MCI and dementia included 10 variables, among them ZSCAN18, PRKD3, SPANXN4, DDX43, saturated fatty acids, PPP3CA, NFATC4, IL-8, PAK6, and PDGFB. Another study evaluated plasma kallikrein-8 as a potential biomarker for early diagnosis at the MCI stage using a fully automated immunoassay.

Other publications explored neurobiology and functional correlates of MCI. A neuroimaging study investigated hypothalamic volume, microstructure, and function in aging and reported associations between hypothalamic alterations and cognitive and functional decline in patients with MCI. An exercise physiology study examined plasma myokine and cytokine responses to a single 6-minute walking bout in older adults with and without MCI and found a suppressed brain-derived neurotrophic factor response in MCI. These findings suggest that MCI may be accompanied by measurable changes in brain structure and peripheral signaling responses.

Intervention-oriented studies also addressed supportive technologies and modifiable risk factors. The SMART4MD study evaluated a customized tablet app designed to improve or maintain quality of life for people with MCI and their informal caregivers, while a cost-effectiveness analysis was performed for this support, monitoring, and reminder technology. In addition, a protocol for the SOUND trial proposed a family-supported hearing aid use behavior intervention for older adults with hearing loss and MCI, aiming to improve cognitive function. Another protocol, TOPS-CSVD, planned to test Tongxinluo capsules in patients with cerebral small vessel disease and MCI. Finally, a real-world retrospective cohort study compared tirzepatide versus semaglutide for prevention of MCI, dementia, and Alzheimer’s disease in type 2 diabetes, reflecting interest in glucagon-like peptide-1 agonists as potential neurocognitive risk-modifying therapies.

Key Publications

• NEWJun Real-world effectiveness of monoclonal antibody lecanemab versus acetylcholinesterase inhibitors in Alzheimer's disease: a target trial emulation. (Alzheimer's research & therapy, 2026, PMID 42332768): "Therefore, this study aimed to compare the safety and effectiveness of initiating lecanemab versus AChEIs in patients with mild cognitive impairment (MCI) or AD."
• NEWJun Omics signature of new-onset mild cognitive impairment and dementia in a population-based study. (Scientific reports, 2026, PMID 42303781): "...associations with baseline prevalent MCI and dementia."
• May Support, Monitoring, and Reminder Technology for Mild Dementia (SMART4MD) for People With Mild Cognitive Impairment and Their Informal Caregivers: Cost-Effectiveness Analysis. (JMIR human factors, 2026, PMID 42172614): "Support, Monitoring, and Reminder Technology for Mild Dementia (SMART4MD), a customized tablet app, was developed to improve or maintain the quality of life of people with mild cognitive impairment (MCI) and their informal caregivers."
• May Family-supported hearing aid use behaviour intervention to improve outcomes in older adults at high risk for dementia (SOUND): study protocol for a randomised controlled trial. (BMJ open, 2026, PMID 42156151): "Our study aims to explore whether a family-supported hearing aid use behaviour intervention, guided by the integrated framework of self-determination theory, technology acceptance model and family social support theory, can improve cognitive function in Chinese older adults with both HL and mild cognitive impairment (MCI)."
• Jun Hypothalamic microstructure and function are associated with mild cognitive impairment in aging. (Brain research bulletin, 2026, PMID 42092705): "This study aimed to comprehensively investigate the macroscopic volumetric and microstructural alterations within hypothalamic subregions in patients with mild cognitive impairment (MCI) and their associations with cognitive and functional decline."
• May Dual-model deep learning for Alzheimer's prognostication. (Computers in biology and medicine, 2026, PMID 41962454): "and a deep survival model estimates time-to-conversion from mild cognitive impairment to dementia."
• Apr Suppressed brain-derived neurotrophic factor response to 6 min walking exercise in mild cognitive impairment. (Brain, behavior, and immunity, 2026, PMID 41912101): "We examined whether a single bout of walking exercise induces distinct changes in plasma myokine and cytokine concentrations in older adults with and without mild cognitive impairment (MCI)."
• May Tirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer's disease in type 2 diabetes: A real-world, retrospective cohort study. (Journal of diabetes and its complications, 2026, PMID 41825212): "Tirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer's disease in type 2 diabetes: A real-world, retrospective cohort study."
• Jun A fully automated immunoassay for plasma kallikrein-8: Development and evaluation in mild cognitive impairment. (Brain research, 2026, PMID 41819517): "we aimed to evaluate plasma kallikrein-8 (KLK8) as a potential biomarker for early diagnosis at the mild cognitive impairment (MCI) stage."
• Apr Tongxinluo capsule in the treatment of cerebral small vessel disease: protocol of a randomised, double-blind, placebo-controlled, multicentre clinical study (TOPS-CSVD). (Stroke and vascular neurology, 2026, PMID 40935402): "This trial aims to investigate the potential benefits of Tongxinluo capsules in Chinese patients with cerebral small vessel disease (CSVD) who have been diagnosed with mild cognitive impairment."